Provider Summary
Primary Uses
Add-on maintenance treatment for severe eosinophilic asthma; also used for EGPA per indication.
Mechanism of Action
Anti‑IL‑5 receptor α monoclonal antibody leading to eosinophil depletion (ADCC).
Pre-treatment / Baseline Requirement
Confirm eosinophilic phenotype; treat helminth infection when applicable; screen for active infection; vaccination review.
Common side effects
Headache, pharyngitis (sore throat), injection-site reactions.
Serious adverse effects / key risks
Hypersensitivity reactions, including anaphylaxis (rare).
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Add-on maintenance treatment for severe eosinophilic asthma; also used for EGPA per indication.
How it works
Anti‑IL‑5 receptor α monoclonal antibody leading to eosinophil depletion.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Headache, pharyngitis, injection-site reactions.
Get urgent help for:
Hypersensitivity reactions, including anaphylaxis.
On treatment Day:
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.